Terms: = Ovarian cancer AND PR, PGR, progesterone receptor AND Prognosis
206 results:
1. Clinicopathological pattern of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 over-expression of epithelial ovarian carcinomas in Nigeria.
Ajani MA; Lawan A; Oke T; Khramtsova G; Nwanji I; Salami A; Awolude O; Ebili H; Onwukamuche ME; Sveen E; Yoshimatsu T; Olopade OI
Afr Health Sci; 2023 Sep; 23(3):236-244. PubMed ID: 38357171
[TBL] [Abstract] [Full Text] [Related]
2. The management of uterine tumor resembling an ovarian sex cord tumor (UTROSCT): case series and literature review.
Lin J; Liu L; Wang L; Ma N; Zhang K; Xie N; Yu H; Deng S; Sun Y
World J Surg Oncol; 2024 Feb; 22(1):42. PubMed ID: 38310233
[TBL] [Abstract] [Full Text] [Related]
3. Case report: Interstitial implantation radiotherapy combined with immunotherapy and GM-CSF in oligometastatic platinum-resistant ovarian cancer.
Qin Y; Huang S; Tang J; Fan Y; Deng X; Guan P; Zhang Z; Wen Q; Li D
Front Immunol; 2023; 14():1329951. PubMed ID: 38235148
[TBL] [Abstract] [Full Text] [Related]
4. Correlation of clinicopathological and prognostic characteristics between endometriosis-associated and primary ovarian cancer.
Wang H; Chen C; Wang D; Zhu Y; Chen P
BMC Cancer; 2023 Dec; 23(1):1210. PubMed ID: 38066448
[TBL] [Abstract] [Full Text] [Related]
5. In Silico Identification of a BRCA1:miR-29:DNMT3 Axis Involved in the Control of Hormone receptors in BRCA1-Associated Breast cancers.
Santarosa M; Baldazzi D; Armellin M; Maestro R
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373065
[TBL] [Abstract] [Full Text] [Related]
6. Distinct histological and clinical features associated with pure uterine serous carcinoma: A single institution experience.
Zhi W; Zhan Y; He C; Jin Y
Ann Diagn Pathol; 2023 Oct; 66():152173. PubMed ID: 37352704
[TBL] [Abstract] [Full Text] [Related]
7. Primary ovarian Small Cell Carcinoma of Pulmonary Type: Analysis of 6 Cases and Review of 31 Cases in the Literatures.
Chen X; Liu HL; Wang JS; Zhao FH
Chin Med Sci J; 2023 Jun; 38(2):130-137. PubMed ID: 37286512
[TBL] [Abstract] [Full Text] [Related]
8. Differential molecular pathway expression according to chemotherapeutic response in ovarian clear cell carcinoma.
Yin M; Lu C; Zhou H; Liu Q; Yang J
BMC Womens Health; 2023 Jun; 23(1):298. PubMed ID: 37270486
[TBL] [Abstract] [Full Text] [Related]
9. The bioinformatics analysis of the clinicopathological and prognostic significances of REG4 mRNA in gynecological cancers.
Zhang CY; Zhang L; Wang ZM; Ren DH; Zheng HC
J Obstet Gynaecol; 2023 Dec; 43(1):2213764. PubMed ID: 37218920
[TBL] [Abstract] [Full Text] [Related]
10. Involvement in Tumorigenesis and Clinical Significance of CXCL1 in Reproductive cancers: Breast cancer, Cervical cancer, Endometrial cancer, ovarian cancer and Prostate cancer.
Korbecki J; Bosiacki M; Barczak K; Łagocka R; Brodowska A; Chlubek D; Baranowska-Bosiacka I
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108425
[TBL] [Abstract] [Full Text] [Related]
11. Th2 cells infiltrating high-grade serous ovarian cancer: a feature that may account for the poor prognosis.
Su H; Jin Y; Tao C; Yang H; Yang E; Zhang WG; Feng F
J Gynecol Oncol; 2023 Jul; 34(4):e48. PubMed ID: 36998223
[TBL] [Abstract] [Full Text] [Related]
12. Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant ovarian High-Grade Serous Carcinoma: The OCTOPUS Multicenter, Phase 2, Randomized Clinical Trial.
Banerjee S; Giannone G; Clamp AR; Ennis DP; Glasspool RM; Herbertson R; Krell J; Riisnaes R; Mirza HB; Cheng Z; McDermott J; Green C; Kristeleit RS; George A; Gourley C; Lewsley LA; Rai D; Banerji U; Hinsley S; McNeish IA
JAMA Oncol; 2023 May; 9(5):675-682. PubMed ID: 36928279
[TBL] [Abstract] [Full Text] [Related]
13. Molecular Landscape of Mullerian Clear Cell Carcinomas Identifies The cancer Genome Atlas-like Prognostic Subgroups.
Irshaid L; Costigan DC; Dong F; Matulonis UA; Nucci MR; Kolin DL
Mod Pathol; 2023 May; 36(5):100123. PubMed ID: 36857998
[TBL] [Abstract] [Full Text] [Related]
14. A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors.
Němejcová K; Šafanda A; Bártů MK; Michálková R; Drozenová J; Fabian P; Hausnerová J; Laco J; Matěj R; Méhes G; Škapa P; Stružinská I; Dundr P
Diagn Pathol; 2023 Feb; 18(1):32. PubMed ID: 36855066
[TBL] [Abstract] [Full Text] [Related]
15. Grade and Estrogen receptor Expression Identify a Subset of No Specific Molecular Profile Endometrial Carcinomas at a Very Low Risk of Disease-Specific Death.
Jamieson A; Huvila J; Chiu D; Thompson EF; Scott S; Salvador S; Vicus D; Helpman L; Gotlieb W; Kean S; Samouelian V; Köbel M; Kinloch M; Parra-Harran C; Offman S; Grondin K; Irving J; Lum A; Senz J; Leung S; McConechy MK; Plante M; Kommoss S; Huntsman DG; Talhouk A; Gilks CB; McAlpine JN
Mod Pathol; 2023 Apr; 36(4):100085. PubMed ID: 36788084
[TBL] [Abstract] [Full Text] [Related]
16. Phase II study of gemcitabine, cisplatin, and bevacizumab for first recurrent and refractory ovarian clear cell carcinoma Kansai Clinical Oncology Group-G1601.
Ito K; Nakagawa M; Shimokawa M; Hori K; Tashima L; Goto M; Yanagida S; Suzuki J; Kaya R; Kawabata A; Yamada K; Park J; Nasu H; Nishio S; Kondo E; Kaneda M; Tsubamoto H; Arakawa A; Nagasawa T; Motohashi T
Anticancer Drugs; 2023 Aug; 34(7):857-865. PubMed ID: 36729915
[TBL] [Abstract] [Full Text] [Related]
17. The presence of clear cell glands around the ovarian endometrioid cyst has an association with clear cell carcinoma.
Qu J; Yu J; Zhong S; Wang W; Wang Q; Du B
Virchows Arch; 2023 Jun; 482(6):1021-1034. PubMed ID: 36580137
[TBL] [Abstract] [Full Text] [Related]
18. Targeting the FGF/FGFR axis and its co-alteration allies.
Uehara Y; Ikeda S; Kim KH; Lim HJ; Adashek JJ; Persha HE; Okamura R; Lee S; Sicklick JK; Kato S; Kurzrock R
ESMO Open; 2022 Dec; 7(6):100647. PubMed ID: 36455506
[TBL] [Abstract] [Full Text] [Related]
19. A case report of small cell ovarian neuroendocrine carcinoma combined with immunochemotherapy.
Zhu YX; Gao XP; Xin L; Jia YC
Medicine (Baltimore); 2022 Nov; 101(46):e31445. PubMed ID: 36401483
[TBL] [Abstract] [Full Text] [Related]
20. Fertility-Sparing Approach in Patients with Endometrioid Endometrial cancer Grade 2 Stage IA (FIGO): A Qualitative Systematic Review.
Giampaolino P; Cafasso V; Boccia D; Ascione M; Mercorio A; Viciglione F; Palumbo M; Serafino P; Buonfantino C; De Angelis MC; Verrazzo P; Grasso G; Gullo G; Bifulco G; Della Corte L
Biomed Res Int; 2022; 2022():4070368. PubMed ID: 36203482
[TBL] [Abstract] [Full Text] [Related]
[Next]